Lance Gleich
Papers
1
Total Citations
4
H-Index
1
About
Lance Gleich is a researcher whose early work focused on advancing drug development through innovative assay technologies. His key contributions lie in the field of ADME/Tox (Absorption, Distribution, Metabolism, Excretion, and Toxicity) screening, a critical step in the pharmaceutical pipeline. His most notable work, "ADMET Assays on Tecan's LabCD-ADMET System" (2003), demonstrated the feasibility of miniaturizing and automating three essential assays—Cytochrome P450 Inhibition, Serum Protein Binding, and P-glycoprotein Interaction—on a microfluidic LabCD platform. This pioneering approach aimed to accelerate early-stage drug discovery by enabling higher throughput and reduced reagent consumption. Though his work has garnered a modest citation count of 4, it represents an important early exploration into integrating microfluidics with critical pharmacokinetic profiling, laying groundwork for later advancements in automated, chip-based drug screening. Gleich’s research underscores the ongoing industry challenge of efficiently evaluating drug candidates’ safety and efficacy, highlighting his role in the evolution of preclinical testing methodologies.
Research Focus
Key Achievements
Top Papers
- 1ADMET Assays on Tecan's LabCD-ADMET System4 citations · 2003